博瑞医药: 董事会对独立董事独立性自查情况的专项报告

Group 1 - The company conducted an evaluation of the independence of its independent directors, confirming that all three independent directors meet the independence requirements set by relevant regulations [1] - The independent directors, Cheng Zengjiang, Xu Dongdong, and Wu Yinghua, have no conflicts of interest with the company or its major shareholders, allowing them to perform their duties independently [1] - The board of directors affirmed that the independent directors maintained a high level of independence throughout the year 2024, providing impartial and professional opinions for the company's decision-making [1]